Bank of America Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Neutral
More News related to ALXN
- Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2009 Results on February 11, 2010
- Oppenheimer Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Perform
- Alexion to Present at the 28th Annual JP Morgan Healthcare Conference
- Alexion Pharma (ALXN) Reports Presence of Type II PNH Cells Correlated with Thrombocytopenia
- Alexion Pharma (ALXN) Updates on Commissioning of Rhode Island Facility as Second Supply Source for Soliris
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Bank of America initiates coverage on Alexion Pharmaceuticals (Nasdaq: ALXN) with a Neutral rating. Price target $53.
To see more analyst ratings on ALXN Click Here.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions.
Related Categories
New CoverageStocks Mentioned
+0.94Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
